好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Sporadic Late Onset Nemaline Myopathy Presenting with Cranial Mononeuropathies
Neuromuscular and Clinical Neurophysiology (EMG)
P3 - Poster Session 3 (11:45 AM-12:45 PM)
11-019

To highlight an unusual presentation of sporadic late onset nemaline myopathy (SLONM) initially manifesting with cranial mononeuropathies.

SLONM is a rare muscle disease presenting in adulthood with progressive muscle weakness. Histopathologically, it is marked by the presence of nemaline rods in muscle fibers, with minimal to no inflammation. SLONM can present with a wide variety of manifestations, including bulbar, axial and proximal weakness. Severe neck or back pain at onset is relatively common in SLONM. However, cranial mononeuropathies as an initial presentation have not yet been reported.

NA

The first patient was a 49-year-old female who presented with a 3-year history of left-followed-by-right sided facial numbness and burning sensation, primarily affecting the V1 and V2 distributions, and dysgeusia. One year later, she developed progressive lower followed by upper limb weakness, dyspnea, and dysphagia. Examination showed bulbar and proximal limb weakness, severe bilateral facial sensory loss, and mild length-dependent sensory deficits. The second patient was a 75-year-old female who presented with one-year history of left-more-than-right sided facial numbness, and dysgeusia, followed by mild dysphagia and head drop. Examination showed left hemiface numbness, tongue weakness, and head drop without limb weakness. EMG in both patients demonstrated bilateral trigeminal neuropathies and a myopathy with fibrillation potentials. Both patients had an IgG monoclonal protein and normal creatine kinase levels. HIV testing was negative in both. Diagnosis of SLONM was established by muscle histopathology demonstrating the accumulation of nemaline rods in mostly atrophic muscle fibers. First patient is being treated with IVIG. The second was treated with lenalidomide with partial improvement in her weakness and facial numbness.

Herein, we underscore the rare occurrence of cranial neuropathies at presentation in patients with SLONM, expanding the clinical spectrum of this condition.

Authors/Disclosures
Ibrahim Shammas, MD
PRESENTER
Dr. Shammas has nothing to disclose.
Samuel Feher, MD Dr. Feher has nothing to disclose.
Andre Granger, MD, MBA (Mayo Clinic) Dr. Granger has nothing to disclose.
Taxiarchis Kourelis, MD Dr. Kourelis has nothing to disclose.
Elie Naddaf, MD (Mayo Clinic) Dr. Naddaf has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Expert Connect. Dr. Naddaf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Klick, Inc. Dr. Naddaf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for WebMD. Dr. Naddaf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson and Johnson. Dr. Naddaf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arcellx. The institution of Dr. Naddaf has received research support from NIAMS. The institution of Dr. Naddaf has received research support from Fulcrum therapeutics. The institution of Dr. Naddaf has received research support from Abcuro. The institution of Dr. Naddaf has received research support from Cabaletta . The institution of Dr. Naddaf has received research support from Arcellx.